Oramed Pharmaceuticals' Israeli subsidiary, Oramed Ltd has received $807,000 government grant from the Office of the Chief Scientist (OCS) at the Ministry of Industry, Trade and Labor of Israel.
Subscribe to our email newsletter
The funds will be designated and used by Oramed Ltd to support further R&D and clinical study of its Oral Insulin capsule and Oral GLP1-Analog.
Oramed Pharmaceuticals CEO Nadav Kidron Esq said that they are pleased to have received the support of the Office of the Chief Scientist for the second year in a row.
"This grant will allow for further development of our product pipeline," Esq said.
Oramed Pharmaceuticals is a technology company deals with oral delivery solutions for drugs and vaccines presently delivered via injection.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.